Part 2 of interview w/ Access Pharmaceuticals C.E.O. Jeffery B. Davis

Here is part 2 of the interview with Access Pharmaceuticals Jeffery B. Davis where he talks about development of Cobalamin, ProLindac, & Thiarabine, and how they all will be of great importance to the future of healthcare.

http://www.accesspharma.com/newsroom/q-a-with-access-pharmaceuticals-ceo-jeffrey-b-davis-part-2-cobalamin-prolindac-and-thiarabine/

Part 1 of an interview with Access Pharmaceuticals' C.E.O. Jeffrey B. Davis who offers insight on the Access Pharmaceuticals corporate overview, and the launch of revolutionary Chemotherapy treatment product MuGard.

http://www.accesspharma.com/newsroom/q-a-with-access-pharmaceuticals-ceo-jeffrey-b-davis-pt-1-corporate-overview-and-mugard/

Access Pharmaceuticals, Inc. (ACCP) - Financial and Strategic Analysis Review - market research report on Reportlinker

This is a Financial & Strategic Analysis Review of Access Pharmaceuticals, as given by the market research department of Reportlinker. com.

Access Pharmaceuticals, Inc. (ACCP) - Financial and Strategic Analysis Review - market research report on Reportlinker

Access Pharma's C.E.O. Jeff Davis sits down with OutsideIn Research

Access Pharmaceuticals (OTCBB: ACCP) CEO Jeffrey Davis discusses MuGards' recent FDA approval with OutsideIn Research.

Access Pharmaceuticals is taking aim at the estimated one billion dollar market in the treatment of oral mucositis (OM). OM is a painful ulceration of the mucous membranes lining the digestive tract. OM is commonly brought on by chemotherapy and radiation treatments administered to cancer patients. Estimates are 90% of all patients undergoing radiation treatment and 40% receiving chemotherapy get mucositis.

MuGard has a lower cost per patient, and is easier to administer compared with other gel based treatments on the market. Zacks Equity Research estimates MuGard sales will see a peak of $300 million and capture a quarter of the OM treatment market. As MuGard gains acceptance in the medical communities, Access Pharmaceuticals should see a significant rise in bottom line profits.

To view the entire interview with OutsideIn Research please visit www.outsideinresearch.com/qaaccp/